Cabazitaxel
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1403 publications
Integrated analytical quality by design enabled stability-indicating LC-MS method for cabazitaxel: forced degradation profiling, in silico pharmacokinetic prediction, and multi-metric greenness assessment.
Journal: Analytical methods : advancing methods and applications
Published: October 05, 2026
Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
Journal: Cancers
Published: August 27, 2026
A Review on Analytical Insights into Impurity Profiling of Selected Anticancer Agents: Tinibs and Taxanes.
Journal: Critical reviews in analytical chemistry
Published: August 23, 2026
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance.
Journal: Expert opinion on investigational drugs
Published: August 19, 2026
Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective.
Journal: Journal of medical economics
Published: August 07, 2026
Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis.
Journal: Journal of clinical medicine
Published: July 29, 2026
Self-assembled nanocomplexes of polyphenol-modified prodrugs and transferrin enable cascade-targeted and redox-activated chemotherapy.
Journal: Materials horizons
Published: July 28, 2026
Reply to "Cost-Effectiveness of 177Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations".
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 27, 2026
Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).
Journal: Current oncology (Toronto, Ont.)
Published: July 21, 2026
A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guérin-Unresponsive Urothelial Carcinoma of the Bladder.
Journal: The Journal of urology
Published: July 17, 2026
Prostate Cancer: Etiology, Diagnosis, and Treatment.
Journal: Serican journal of medicine
Published: June 30, 2026
Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: Clinical genitourinary cancer
Published: June 11, 2026
Last Updated: 11/08/2026